Recent Updates

Modified on: 
Dec 20, 2019
Share
Twitter Facebook LinkedIn Forward

BloodTechNet educational resources

The BloodTechNet program was launched in 2011 to facilitate the development of innovative educational resources that support the Transfusion, Cellular Therapy and Transplantation communities in Canada.

Transfusion
Organs and Tissues
Stem Cells
Share
Twitter Facebook LinkedIn Forward
Published: 
Aug 8, 2019

Donor Selection, Donor Testing and Pathogen Reduction

Chapter 6

All blood transfused in Canada is collected from volunteer donors. To ensure the safety of the blood products, donors are carefully screened against an extended list of eligibility criteria. In addition, the donated blood is tested to identify the donor’s blood group and to detect blood group antibodies and transfusion-transmissible pathogens. Donor eligibility criteria and testing also benefit the donors by, for example, reducing potential blood donation-related health risks.

Transfusion
Share
Twitter Facebook LinkedIn Forward
Published: 
Sep 10, 2019

Fractionated Blood Products and Associated Pathogen Safety

Chapter 7

Background

Originally all plasma fractionation products were derived from pooled human plasma. Increasingly, many plasma proteins are manufactured by biotechnology as recombinant proteins, without need for donated plasma; depending on the plasma protein product, either a recombinant or fractionated product, or both are available in Canada.

Transfusion
more

Upcoming Events

Topic Teaching: MMA: Monocyte Monolayer Assay

Share
Twitter Facebook LinkedIn Forward
When
March 31, 2020 | 12:00PM to 1:00PM
Where

Toronto/Webinar

Presented by:

Ms. Nadia Baillargeon
Ms. Josee Perrault
Héma-Québec

Objectives:

1.    Describe the Monocyte Monolayer Assay (MMA) technique.
2.    Describe the application of MMA using a case study approach.
3.    Describe the MMA test settings and future directions at Héma Québec.

Referencees:

N/A

 

Transfusion

Policy, Commercialization and Knowledge transfer

Share
Twitter Facebook LinkedIn Forward
When
April 6, 2020 | 4:00PM to 5:00PM
Where

Webinar

April 6, 2020 – 4pm ET
Speaker: Dr. Darren Freed
Click here to navigate to the webinar link.

The Cross-Cutting Priorities Webinar Series will launch on December 2, 2019 at 4pm ET and extend until April 20, 2020. The purpose of the webinar series is to emphasize the importance of having one or more cross-cutting priorities incorporated in research projects, and practical steps on how to do so.

Organs and Tissues

Topic Teaching: Blood Product Support for VLBW infants

Share
Twitter Facebook LinkedIn Forward
When
April 7, 2020 | 12:00PM to 1:00PM
Where

Toronto/Webinar

Details to follow.

 

Note: The session is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada.

Transfusion
more

Blog

Modified on: 
Mar 25, 2020
Share
Twitter Facebook LinkedIn Forward

A novel microfluidic device to aid in the search for red blood cell “super-storers”

Donated red blood cell units are a vital component of patient care, supporting patients with a wide variety of disorders. However, not all blood units are the same, and the benefit they can deliver to a patient can vary from unit to unit. Read on to learn about a unique device developed in a research laboratory at the Centre for Blood Research that can sort stored red blood cells based on their “squeezability”. This reflects how well red blood cells can squeeze their way through the circulation after a transfusion and could help identify “super-storers”.

Transfusion

Modified on: 
Mar 11, 2020
Share
Twitter Facebook LinkedIn Forward

Fibrinogen replacement products: how do they stack up against each other?

For patients who have cardiac surgery, the risk of severe blood loss is high if they have a condition called acquired hypofibrinogenemia — this means they have an undersupply of an essential blood clotting protein called fibrinogen. Doctors aim to minimize their bleeding with a fibrinogen replacement product, either cryoprecipitate or fibrinogen concentrate, to restore clotting factors to normal levels. A recent study that compared both products could have an impact on how cardiac patients are treated in Canada.

Transfusion

Modified on: 
Mar 9, 2020
Share
Twitter Facebook LinkedIn Forward

Why you won’t get COVID-19 from a blood transfusion

“There is absolutely no evidence of transfusion transmission for COVID-19, or any other coronavirus,” says Dr. Steven Drews, associate director of microbiology at Canadian Blood Services.

Transfusion

more